REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Research/Paper
Back to Research Library
bioRxivPreprint

A Xenopus neuromast bioassay for chemical ototoxicity

Knight, V. B., Luna, A. R., Serrano, E.
biorxiv preprint2022DOI: 10.1101/2021.12.30.474606

Citations

0

Subjects

Non-Human

Study Context

This is a preprint — it has not yet completed peer review. The findings should be interpreted with caution, though preprints allow rapid dissemination of potentially important results.

Citation

Knight, V. B., Luna, A. R., Serrano, E.. (2022). A Xenopus neuromast bioassay for chemical ototoxicity. biorxiv preprint. https://doi.org/10.1101/2021.12.30.474606

View full text on bioRxiv

This content is derived from peer-reviewed research for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide-based therapy.